VERTERO
LIVE

Serial Number

99262902

Owner

Axial Therapeutics, Inc.

Attorney

Ian W. Gillies

Filing Date

Jul 1, 2025

Add to watchlist:

No watchlists yet
View on USPTO

VERTERO Trademark

Serial Number: 99262902

VERTERO is a trademark filed by Axial Therapeutics, Inc. on July 1, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Axial Therapeutics, Inc.

3579 Valley Centre Drive, Suite 300
San Diego, CA 92130

Entity Type: 03

Trademark Details

Filing Date

July 1, 2025

Registration Date

Not Registered

Published for Opposition

December 23, 2025

Goods & Services

Providing medical research and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic pharmaceutical products, microbe-targeted pharmaceutical products, or host-targeted pharmaceutical products; research in the fields of conducting clinical trials for others, biochemistry, and biotechnology

Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic, microbe-targeted, or host-targeted pharmaceuticals

Probiotic pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases; Microbe-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases; Host-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases; Chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, and gastrointestinal and immunological diseases

Chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic pharmaceutical preparations, microbe-targeted pharmaceutical preparations, or host-targeted pharmaceutical preparations for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, and gastrointestinal and immunological diseases; Chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic pharmaceutical preparations, microbe-targeted pharmaceutical preparations, or host-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 17, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 23, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 23, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 17, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 21, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 21, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 21, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 21, 2025 CNEA
ASSIGNED TO EXAMINER
Nov 19, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 6, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jul 1, 2025 MAFR
NEW APPLICATION ENTERED
Jul 1, 2025 NWAP